Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, uncertainties regarding our future operating results, the risk that our product candidates will not obtain the requisite regulatory approvals to commercialize or that the future sales of our product candidates may be less than expected, and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2009 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Reston, VA (PRWEB) July 28, 2014 ... leading nonprofit authority on the use of health IT ... its Health Plan Identifier (HPID) Workgroup has ... Between a Health Plan and Payer?” The HPID Workgroup, ... worked closely with the Centers for Medicare and Medicaid ...
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)... Hershey, PA & Boston, MA (PRWEB) July 28, 2014 ... into collaboration agreements with two researchers to further develop ... and deadly malignant brain tumor, in combination with their ... executed by ITI and Duke University, are based on ... MHSc, Chief, Division of Neurosurgery at The Preston Robert ...
(Date:7/28/2014)... The global market for biotechnology is expected ... a new study by Grand View Research, Inc. Increasing ... vaccines and drugs in an attempt to improve healthcare ... to drive market demand over the next six years. ... the use of genetically engineered seeds is expected to ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... March 14, 2011 Argentum Medical, LLC today issued a ... versus Noble Biomaterials, Inc. "The most important thing ... patents and it is business as usual for Argentum," said ... case concerned non-patent issues and is currently being appealed. We ...
... Biofuels, a bioenergy crop company using breeding and biotechnology ... it is applying more than 1.6 million genetic markers ... of marker assisted selection (MAS) methods to produce elite, ... the announcement during its presentation at the Biowise 2011 ...
... March 11, 2011 /PRNewswire-Asia-FirstCall/ --Tianyin Pharmaceutical Co., Inc. (NYSE ... specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, ... at the 23rd ROTH Annual OC Growth Stock Conference ... Carlton in Dana Point, California. Dr. James ...
Cached Biology Technology:Argentum Medical Issues Response to Recent Decision in Litigation With Noble Biomaterials 2SG Biofuels Advances Jatropha Biotech Platform with Application of Genetic Markers to Reference Genome 2TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2
(Date:7/28/2014)... Roald Amundsen became the first man to reach the ... years later, an international team of scientists led by ... proven that air pollution from industrial activities arrived long ... from widely spaced locations around the Antarctic continent, including ... and precise reconstruction to date of lead pollution over ...
(Date:7/27/2014)... asteroid strike that wiped them out if it had ... say. , A fresh study using up-to-date fossil records ... a new narrative of the prehistoric creatures, demise, some ... the few million years before a 10km-wide asteroid struck ... This included extensive volcanic activity, changing sea levels and ...
(Date:7/27/2014)... discovered a new species of mayfly in the southern Western ... In fact, this is the first time that any mayfly ... in peninsular India. , The new species, called Labiobaetis ... for his substantial contribution to the understanding of the Ephemeroptera ... a study that describes the new mayfly in the ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... by researchers at Baylor College of Medicine (BCM) and ... DNA sequencing to the patient's bedside, the doctor's office ... battlefield. , "We could eventually do direct detection of ... performed in the laboratory, said Dr. Michael L. Metzker, ...
... in the March 30th edition of the prestigious scientific journal ... UK's national academy of science) shows that the transfer of ... is much larger and more extensive than previously believed. , ... in a contentious debate. It is the first to isolate ...
... "A Method of Reconstituting Nucleic Acid Molecules" today to ... of DermaPlus, Inc. The patent covers methods for recovering ... allow scientists to reassemble everything from prehistoric, extinct animals ... applied by our scientists, brings us closer to our ...
Cached Biology News:Color-blind method opens new doors in DNA sequencing 2Color-blind method opens new doors in DNA sequencing 3Researchers reveal the infectious impact of salmon farms on wild salmon 2Researchers reveal the infectious impact of salmon farms on wild salmon 3Researchers reveal the infectious impact of salmon farms on wild salmon 4Dinosaur DNA? New Patent Covers Degraded DNA recovery 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
... the efficient enrichment of functional endoplasmic ... cell culture. The isolated ER are ... metabolic pathway analysis. Metabolic abnornalities of ... children, cystic fibrosis and many more ...
... for stabilizing 50g of purified RNA samples for ... delivers all of the advantages and applications you ... the RNA can be used for enzymatic applications ... has been optimised for the stabilization of aqueous ...
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: